MHC class II expression in lung cancer.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy represents a significant advancement in lung cancer treatment.
• Understanding the expression of major histocompatibility complex (MHC) Class II proteins is crucial for developing effective immunotherapies.
• This study investigates MHC Class II expression in various lung cancer subtypes.

Purpose of the Study:

• To determine the expression patterns of MHC Class II (DP, DQ, DR) proteins in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines and patient tissues.
• To evaluate the correlation between MHC Class II expression on tumor-infiltrating lymphocytes (TILs) and patient prognosis in NSCLC.

Main Methods:

• Immunohistochemistry (IHC) was employed to assess MHC Class II protein expression.
• The study analyzed 55 NSCLC cell lines, 42 SCLC cell lines, and a total of 278 lung cancer patient tissues.
• MHC Class II expression on TILs was quantified and compared between NSCLC and SCLC, and correlated with survival outcomes.

Main Results:

• MHC Class II expression was detected in 7 (12.7%) NSCLC cell lines, but not in any SCLC cell lines.
• No positive MHC Class II staining was observed on SCLC tumor cells in patient tissues.
• MHC Class II expression on TILs was significantly lower in SCLC compared to NSCLC (P<0.001).
• In NSCLC patients, higher MHC Class II expression on TILs was associated with longer regression-free survival (RFS) and overall survival (OS) (P=0.028 and P=0.014, respectively).

Conclusions:

• MHC Class II is expressed in NSCLC cell lines and tissues, but absent in SCLC cell lines and tumor cells.
• Reduced MHC Class II expression in SCLC may facilitate immune evasion.
• Upregulation of MHC Class II on TILs in NSCLC is a favorable prognostic indicator, suggesting potential therapeutic targets.